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Methylene blue during cardiopulmonary bypass to treat refractory
hypotension in septic endocarditis
M. Grayling, MB, BS, FRCA,a and C. D. Deakin, MA, MD, MRCP, FRCA,b Southampton, United Kingdom
Methylene blue inhibits the enzyme guanylate cy-clase, avoiding the cyclic guanosine 35-mono-phosphate (cGMP)–dependent vasorelaxant ef-fects of nitric oxide in the smooth muscle of
vessels. As well as its uses in the treatment of methemoglobinemia
and malaria and as a medical dye, methylene blue has been used to
treat refractory vasoplegia after cardiopulmonary bypass (CPB),
anaphylaxis, and septic shock.1,2 We describe the first case of
methylene blue used in the CPB prime and in the context of
refractory hypotension in a patient undergoing valve replacement
surgery for infective endocarditis.
Clinical Summary
A 72-year-old man weighing 80 kg was admitted for investigation
of a 3-month history of worsening shortness of breath associated
with malaise, rigors, and swollen ankles. His standard daily pre-
scription included human isophane insulin (Insulatard Nph Hu-
man), ramipril at 2.5 mg, and furosemide at 40 mg. Examination
revealed a temperature of 37.3°C, a blood pressure of 170/53 mm
Hg, and a regular collapsing pulse of 105 beats/min. There was
also a loud early diastolic murmur at the left sternal edge and a
loud pansystolic murmur at the apex. Abnormal results of routine
blood tests included a C-reactive protein level of 69.2 mg/L and a
white blood cell count of 16.4  109 cells/L. A transthoracic
echocardiogram showed two large, highly mobile vegetations on
the aortic valve, with resultant severe aortic regurgitation and a
thickened anterior mitral valve leaflet with moderate mitral regur-
gitation. The patient’s left ventricle was not dilated and was noted
to have reasonable function. A diagnosis of infective endocarditis
was made, and surgery was planned for the next day.
The patient received lorazepam at 1 mg by mouth, morphine at
10 mg intramuscularly, and metoclopramide at 10 mg intramus-
cularly 1 hour before the operation. Radial arterial and peripheral
venous catheters were inserted under local anesthesia. Anesthesia
was induced with midazolam at 8 mg, fentanyl at 500 g, and
pancuronium bromide at 8 mg. The trachea was intubated, and the
patient received mechanical ventilation with 50% oxygen to main-
tain normocapnia. Anesthesia was maintained with isoflurane up to
1.2%.
Persistent hypotension was treated with phenylephrine hydro-
chloride boluses to a total dose of 1.6 mg before CPB. A dopamine
infusion was commenced at 5.2 g/(kg  min), and a norepineph-
rine infusion was started, increasing to 0.02 g/(kg  min).
Despite this, the blood pressure remained low at 100/22 mm Hg.
Subsequent pulse contour analysis with the PulseCO system
(LiDCO, London, United Kingdom), measured a cardiac output of
6.0 L/min and a systemic vascular resistance (SVR) of 550
dynes  s/cm5. On the basis of refractory hypotension and a low
SVR, 160 mg methylene blue (2 mg/kg) was added to the pump
prime before the start of CPB, and once CPB was established a
central venous infusion was commenced at 1 mg/(kg  h). Dopa-
mine was continued at 4.2 g/(kg  min) during CPB, but the
norepinephrine was stopped.
Surgery was uncomplicated with the removal of both the mitral
and aortic valves and replacement with prosthetic 29-mm Carbo-
Medics and 25-mm CarboMedics Top Hat valves (Sulzer Carbo-
Medics Inc, Austin, Tex), respectively.
During CPB no further phenylephrine or norepinephrine was
used, and mean blood pressure was maintained at 50 mm Hg.
Separation from CPB was achieved with dopamine at 4.2 g/
(kg  min) and methylene blue at 0.5 mg/(kg  h). The CPB time
was 155 minutes, and the crossclamp time was 124 minutes. Five
minutes after CPB, the blood pressure was 118/54 mm Hg, the
heart rate was 103 beats/min in sinus rhythm, the cardiac output
was 3.3 L/min, and the SVR was 1600 dynes  s/cm5. Methylene
blue was continued until 30 minutes after CPB. There were no
episodes of cardiac ischemia or arrhythmia after CPB. Before CPB
the ratio of PaO2 to inspired oxygen fraction was 31 kPa, whereas
after CPB it dropped to 14 kPa. The patient was admitted to the
cardiothoracic intensive care unit and extubated 15 hours later.
Subsequent blood and valve cultures isolated Streptococcus mitis.
Discussion
Infective endocarditis is a life-threatening condition that occasion-
ally necessitates emergency valve replacement. It has a spectrum
of clinical presentation and is associated with a systemic inflam-
matory response and the release of endothelial nitric oxide. Many
of the drugs used in cardiac anesthesia and the process of CPB
itself may exacerbate the reduction in SVR through both similar
and unknown mechanisms.1 In this case there was a clear temporal
relationship with the administration of methylene blue and the
reduced quantities of vasopressors required to maintain normoten-
sion through an increase in the SVR.
Sepsis is characterized by arterial vasodilatation, a high cardiac
output despite myocardial depression, and a decreased sensitivity
of the heart and peripheral vessels to sympathomimetic agents. The
myocardial depression and relative insensitivity to sympathomi-
metic agents may be mediated in part by nitric oxide. This has been
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demonstrated in vitro by the inhibition of vascular smooth muscle
and cardiomyocyte contraction by serum from patients with sep-
sis.3 Methylene blue inhibits this process by decreasing intracel-
lular cGMP concentrations through guanylate cyclase inhibition,
and it increases myocardial function, arterial pressure, and oxygen
delivery after a single dose.4 Nitric oxide has many cGMP effects,
such as microbiocidal properties and tumor cell cytotoxicity. In-
hibition of guanylate cyclase may respect these cGMP-indepen-
dent effects as compared with other compounds, such as L-arginine
analogs, thus incurring other clinical benefits.
Detrimental effects of methylene blue on gas exchange may
occur through a process of pulmonary vasoconstriction and dis-
ruption of cGMP-dependent ventilation-perfusion matching. In
contrast, however, hypoxic vasoconstriction in normal animal
lungs is in part mediated by decreases in nitric oxide and cGMP
production.5 Although we demonstrated a fall in the ratio of PaO2
to inspired oxygen fraction immediately after CPB, it would be
difficult to attribute this solely to the effects of methylene blue.
Other uncommon side effects described with the use of meth-
ylene blue include cardiac ischemia and arrhythmias. Although
neither occurred in this case, side effects may become a problem
in patients with critical coronary perfusion or an irritable myocar-
dium. Heparin neutralization by methylene blue has been de-
scribed; however, we had no difficulties with anticoagulation while
the patient was on CPB.6
Conclusion
Patients with an ongoing systemic inflammatory response as a
result of infective endocarditis and those who require CPB for
emergency valve replacement may demonstrate resistant hypoten-
sion related to vasoplegia. Methylene blue should be added to the
CPB prime (2 mg/kg) and continued as an infusion (0.25-2 mg/
[kg  h]) to ameliorate this hypotension. Such a regimen may be
extended to other clinical circumstances in which resistant hypo-
tension is contributed to by activation of the nitric oxide pathway,
such as anaphylaxis and CPB.
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